Precision Lung Cancer Logo

Day Two: Wednesday July 26, 2017

REGISTRATION & COFFEE

8:00

Introduction and Summary

8:15

Biomarkers & Companion Diagnostics

8:30

Biomarkers in cancer immunotherapy: challenges and  opportunities


Enrique Zudaire

Associate Scientific Director


Janssen

9:00

The evolution of TKI-resistance in EGFR mutant NSCLC.

Matt Niederst
Investigator, Oncology Translational Research

 

 

Novartis

9:30

Use of liquid biopsies for detection of biomarkers and resistance mechanisms in NSCLC

 

Daniel Stetson

Associate Principal Scientist

 

AstraZeneca

10:00

Neratinib for treatment of Lung Cancers with Somatic HER2 Mutations

 

Al Lalani

Vice President, Translational Medicine

 

Puma Biotechnology

10:30

Molecular Diagnosis of Lung Cancer: MODAplex Lung Panel concept.

Hadrian Szpurka

Director, Molecular Pathology


Eli Lilly

MORNING REFRESHMENTS & SPEED NETWORKING

11:00

11:30

Genetic characterization of patients with advanced small cell lung cancer from circulating tumor DNA to identify predictive biomarkers

 

Huifeng Niu

Director, Oncology Translational Medicine

 

Takeda Oncology

12:00

An Approach to Conducting Dx-Driven Oncology Trials of Rare Patient Populations


Jason Christensen

Vice President, Diagnostics

 

Ignyta

12:30

 

 

 

TBD



EMD Serono

LUNCH & NETWORKING

1:00

PANEL DISCUSSION

2:00

 

Amir Handzel
Diagnostics and Personalized Medicine

AstraZeneca

more to be announced..

Novel Approaches

2:30

Targeting Rare Oncogenic Kinases in Lung Cancer

 

Michael Rothenberg

Vice President, Research and Development

 

Loxo Oncology

3:00

Targeting immune evasion and therapy resistance through selective Axl inhibition with BGB324

 

Murray Yule

Clinical Development Officer


BerGenBio

AFTERNOON REFRESHMENTS & NETWORKING

3:30

4:00

Overcoming Resistance in Precision Lung Cancer Treatment

 

Jean Cui

Founder and Chief Scientific Officer

TP Therapeutics

4:30

 

Targeted and Personalized Peptide Therapy to Treat Small Cell Lung Cancer

 

Christopher Adams

Chief Executive Officer

 

Andarix

 

5:00

XMT-1536, a highly potent NaPi2b-targeted Dolaflexin® antibody-drug conjugate

 

Natalya Bodyak

Executive Director, External Scientific Affairs

 

Mersana

 

SUMMARY & CLOSE OF CONFERENCE

5:30

VIEW PREVIOUS DAY

DOWNLOAD EVENT GUIDE

Complete the form below to download the PDF

NEO SYNTH International House, 24 Holborn Viaduct, London EC1A 2BN

contact@neo-synth.com

(+1) 617.500.5172

Submitting Form...

The server encountered an error.

Request received. Please allow some time for processing - You will receive a manual response within a few hours.

Your details will not be shared with a third party

Copyright © 2017| All content produced by: neo-synth ltd.

DOWNLOAD GUIDE

Complete the form below to download the PDF